Agile Therapeutics, Inc. – NASDAQ:AGRX
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
Agile Therapeutics stock price monthly change
+298.03%
month
Agile Therapeutics stock price quarterly change
+397.39%
quarter
Agile Therapeutics stock price yearly change
-55.59%
year
Agile Therapeutics key metrics
Market Cap | 10.42M |
Enterprise value | 333.83M |
P/E | -6.7 |
EV/Sales | 30.66 |
EV/EBITDA | -8.85 |
Price/Sales | 30.94 |
Price/Book | -60.75 |
PEG ratio | -0.06 |
EPS | -3.65 |
Revenue | 21.49M |
EBITDA | -15.58M |
Income | -7.79M |
Revenue Q/Q | 49.90% |
Revenue Y/Y | 66.15% |
Profit margin | -437.14% |
Oper. margin | -380.64% |
Gross margin | 37.2% |
EBIT margin | -380.64% |
EBITDA margin | -72.49% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAgile Therapeutics stock price history
Agile Therapeutics stock forecast
Agile Therapeutics financial statements
| Jun 2023 | 5.50M | -3.80M | -69.22% |
|---|---|---|---|
| Sep 2023 | 6.66M | -799K | -11.99% |
| Dec 2023 | 3.61M | -4.47M | -123.69% |
| Mar 2024 | 5.71M | 1.28M | 22.46% |
| Sep 2025 | 17.06M | 0 | |
|---|---|---|---|
| Oct 2025 | 17.06M | 0 | |
| Dec 2025 | 17.72M | 0 | |
| Dec 2025 | 17.72M | 0 |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 12571000 | 24.69M | 196.42% |
|---|---|---|---|
| Sep 2023 | 10889000 | 23.3M | 213.98% |
| Dec 2023 | 10255000 | 26.57M | 259.12% |
| Mar 2024 | 12610000 | 22.93M | 181.87% |
| Jun 2023 | -8.51M | 0 | 6.87M |
|---|---|---|---|
| Sep 2023 | 365K | 0 | -278K |
| Dec 2023 | 172K | 0 | -487K |
| Mar 2024 | -2.47M | 0 | 2.53M |
Agile Therapeutics alternative data
| Aug 2023 | 22 |
|---|---|
| Sep 2023 | 22 |
| Oct 2023 | 22 |
| Nov 2023 | 22 |
| Dec 2023 | 22 |
| Jan 2024 | 22 |
| Feb 2024 | 22 |
| Mar 2024 | 22 |
| Apr 2024 | 22 |
| May 2024 | 19 |
| Jun 2024 | 19 |
| Jul 2024 | 19 |
Agile Therapeutics other data
41.78%
+1.62%
of AGRX is owned by hedge funds
32
-13
1.01M
+72.55K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Oct 2021 | 8598312 | 0 |
| Aug 2022 | 50000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ALTOMARI ALFRED director, officer.. | Common Stock | 50,000 | $0.45 | $22,500 | ||
Purchase | PERCEPTIVE ADVISORS LLC 10 percent owner | Warrants (right to buy) | 2,687,280 | $0.85 | $2,284,188 | ||
Purchase | PERCEPTIVE ADVISORS LLC 10 percent owner | Common Stock | 5,734,560 | $0.85 | $4,874,376 | ||
Purchase | ALTOMARI ALFRED director, officer.. | Warrants (right to buy) | 29,412 | $0.85 | $25,000 | ||
Purchase | ALTOMARI ALFRED director, officer.. | Common Stock | 58,824 | N/A | N/A | ||
Purchase | REILLY DENNIS officer: Chief Fi.. | Warrants (right to buy) | 29,412 | $0.85 | $25,000 | ||
Purchase | REILLY DENNIS officer: Chief Fi.. | Common Stock | 58,824 | N/A | N/A | ||
Purchase | ALTOMARI ALFRED director, officer.. | Common Stock | 26,200 | $1.26 | $33,091 | ||
Purchase | REILLY DENNIS officer: Chief Fi.. | Common Stock | 50,000 | $1.08 | $54,150 | ||
Purchase | ALTOMARI ALFRED director, officer.. | Common Stock | 20,000 | $1.61 | $32,200 |
| Patent |
|---|
Application Filling date: 19 Oct 2020 Issue date: 4 Feb 2021 |
Application Filling date: 13 Oct 2020 Issue date: 28 Jan 2021 |
Application Filling date: 13 Oct 2020 Issue date: 28 Jan 2021 |
Application Filling date: 13 Mar 2018 Issue date: 30 Apr 2020 |
Application Filling date: 10 Jun 2019 Issue date: 27 Feb 2020 |
Application Filling date: 10 Jun 2019 Issue date: 27 Feb 2020 |
| Quarter | Transcript |
|---|---|
| Q4 2023 28 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 12 May 2023 | Q1 2023 Earnings Call Transcript |
-
When is Agile Therapeutics's next earnings date?
Unfortunately, Agile Therapeutics's (AGRX) next earnings date is currently unknown.
-
Does Agile Therapeutics pay dividends?
No, Agile Therapeutics does not pay dividends.
-
How much money does Agile Therapeutics make?
Agile Therapeutics has a market capitalization of 10.42M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 80.02% to 19.59M US dollars.
-
What is Agile Therapeutics's stock symbol?
Agile Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "AGRX".
-
What is Agile Therapeutics's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Agile Therapeutics?
Shares of Agile Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Agile Therapeutics's key executives?
Agile Therapeutics's management team includes the following people:
- Mr. Alfred F. Altomari Chairman & Chief Executive Officer(age: 66, pay: $894,050)
- Mr. Geoffrey P. Gilmore Senior Vice President, Gen. Counsel & Corporation Sec.(age: 59, pay: $701,530)
- Mr. Dennis P. Reilly Senior Vice President & Chief Financial Officer(age: 66, pay: $550,760)
-
How many employees does Agile Therapeutics have?
As Jul 2024, Agile Therapeutics employs 19 workers, which is 14% less then previous quarter.
-
When Agile Therapeutics went public?
Agile Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 23 May 2014.
-
What is Agile Therapeutics's official website?
The official website for Agile Therapeutics is agiletherapeutics.com.
-
Where are Agile Therapeutics's headquarters?
Agile Therapeutics is headquartered at 500 College Road East, Princeton, NJ.
-
How can i contact Agile Therapeutics?
Agile Therapeutics's mailing address is 500 College Road East, Princeton, NJ and company can be reached via phone at +60 9 683 1880.
Agile Therapeutics company profile:
Agile Therapeutics, Inc.
agiletherapeutics.comExchange:
NASDAQ
Full time employees:
19
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
500 College Road East
Princeton, NJ 08540
Princeton, NJ 08540
CIK: 0001261249
ISIN: US00847L3087
CUSIP: 00847L100
